Department of Surgery, Kosin University Hospital, Busan, Korea.
J Breast Cancer. 2012 Mar;15(1):71-8. doi: 10.4048/jbc.2012.15.1.71. Epub 2012 Mar 28.
The aims of our study were to assess the correlation between serum HER2 and clinicopathologic factors, the effect of serum HER2 on survival rate, and the effect of changes in serum HER2 levels between pre- and post-adjuvant chemotherapy on survival rate.
The study subjects, 200 women with breast cancer, were a subset of patients operated on between January 2005 and December 2006. We evaluated changes in serum HER2 levels between pre- and post-adjuvant chemotherapy.
Being estrogen receptor (ER) negative was also correlated with high serum HER2 (p=0.017). The number of patients with changes in serum HER2 (>20% increased level during the follow-up period) was correlated with advanced T-stage (p=0.010), advanced American Joint Committee on Cancer (AJCC) stage (p=0.015) and poor histologic grade (p=0.001). Univariate analysis for prognostic factors associated with disease-free survival (DFS) revealed that the difference in DFS between those with serum HER2 level <15 ng/mL and those with levels ≥15 ng/mL was statistically significant (p=0.0129) and the changes in serum HER2 levels were also statistically significant (p=0.001). Prognostic factors associated with overall survival revealed that the changes in serum HER2 levels between pre- and post-adjuvant chemotherapy were statistically significant (p=0.0012).
Serum HER2 level is associated with a more advanced degree of axillary lymph node involvement and associated with ER negativity. And Changes in serum HER2 levels are associated with more advanced AJCC staging and histologic tumor grade. There are significant associations between serum HER2 level, changes in serum HER2 levels and 5-year DFS.
本研究旨在评估血清 HER2 与临床病理因素的相关性、血清 HER2 对生存率的影响，以及新辅助化疗前后血清 HER2 水平变化对生存率的影响。
本研究的研究对象为 200 名接受手术治疗的乳腺癌女性患者，为 2005 年 1 月至 2006 年 12 月间手术的患者亚组。我们评估了新辅助化疗前后血清 HER2 水平的变化。
雌激素受体（ER）阴性也与高血清 HER2 相关（p=0.017）。在随访期间，血清 HER2 水平变化（水平升高超过 20%）的患者数量与 T 分期较晚（p=0.010）、美国癌症联合委员会（AJCC）分期较晚（p=0.015）和组织学分级较差（p=0.001）相关。与无病生存（DFS）相关的预后因素的单因素分析显示，血清 HER2 水平<15ng/mL 与≥15ng/mL 患者之间的 DFS 差异具有统计学意义（p=0.0129），血清 HER2 水平变化也具有统计学意义（p=0.001）。与总生存相关的预后因素显示，新辅助化疗前后血清 HER2 水平变化具有统计学意义（p=0.0012）。
血清 HER2 水平与腋窝淋巴结转移程度较晚相关，且与 ER 阴性相关。血清 HER2 水平变化与 AJCC 分期和组织学肿瘤分级较晚相关。血清 HER2 水平、血清 HER2 水平变化与 5 年 DFS 之间存在显著关联。
